E2F Decoy therapy prevents graft failures following CABG

Genetic intervention with E2F Decoy therapy significantly reduces graft failure following coronary artery bypass graft (CABG) surgery. Findings from the first randomised, controlled study of a transcription factor decoy in human coronary artery grafts to prevent intimal hyperplasia and subsequent atherosclerosis were presented at the Scientific Sessions of the American Heart Association [Anaheim, US; November 2001].